ArticleVeterinary research communications2026
Dietary co-supplementation of silymarin and stevioside enhances growth, immunity, and disease resistance in Nile tilapia.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of dietary silymarin, stevioside, and their combined supplementation on the growth performance, physiological responses, immune competence, antioxidant status, and disease resistance of Nile tilapia (Oreochromis niloticus, initial body weight: 2.49 ± 0.10 g) over a 90-day feeding period. Fish were fed either a basal diet (control) or diets supplemented with silymarin (850 mg/kg), stevioside (450 mg/kg), or a combination of both (850 mg/kg silymarin and 450 mg/kg stevioside). Dietary supplementation significantly improved growth performance and feed efficiency, with the combined treatment yielding the greatest response (P < 0.05). Enhanced digestive enzyme activity and improved intestinal and hepatic structure were observed in supplemented groups. Blood biochemical analyses revealed enhanced protein status and reduced glucose, cortisol, and cholesterol levels without adverse effects on hepatic or renal function. Immune and antioxidant responses were enhanced, accompanied by reduced lipid peroxidation. Following Aeromonas hydrophila challenge, supplemented fish reduced cumulative mortality, particularly in the combined treatment. At the molecular level, dietary additives upregulated genes associated with growth, metabolism, immunity, and antioxidant defense. In conclusion, co-supplementation with silymarin (850 mg/kg) and stevioside (450 mg/kg) produced beneficial effects, supporting their potential as functional feed additives to enhance growth performance, health status, and disease resistance in Nile tilapia.
Indexed as
Identifiers
42287461What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.